Necrotizing autoimmune myopathy
A targeted and accelerated approach to diagnosis
Immune-mediated necrotizing myopathy (IMNM), also called necrotizing autoimmune myopathy (NAM), is a rare but serious muscle disease strongly associated with autoantibodies to either signal recognition protein (SRP-IgG) or 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR-IgG). Our testing can provide earlier identification and treatment initiation in patients with IMNM, which is critical to preventing further harm.
Necrotizing autoimmune myopathy Test menu
Necrotizing autoimmune myopathy
Key testing
Advantages
- A single evaluation with the two most pertinent antibodies associated with IMNM: HMGCR-IgG and SRP-IgG. The combination of both antibodies maximizes clinical sensitivity for diagnosing patients with this disease.
- Detection of SRP-IgG using a sensitive immunofluorescence-based assay and then confirming by a second immunoblot technology.
- Antibodies are tested in parallel, providing results in approximately one week.
NOTE: A thorough understanding of a patient’s history, along with clinical examination and laboratory testing, are still needed for a clinic-sero-pathological diagnosis of IMNM.
Highlights
The diagnosis, pathological understanding, and current best treatment options for necrotizing autoimmune myopathy.
Necrotizing autoimmune myopathy (NAM) is a serious but rare muscle disease strongly associated with autoantibodies to either the protein signal recognition particle (SRP) or the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). NAM typically manifests with subacute proximal limb muscle weakness and persistently elevated serum creatine kinase (CK) concentrations, but slower onsets can occur and complicate diagnosis.